ZLCS Share Price

Open 1.15 Change Price %
High 1.29 1 Day 0.03 2.61
Low 1.12 1 Week 0.00 0.00
Close 1.18 1 Month 0.00 0.00
Volume 1155992 1 Year 0.00 0.00
52 Week High 5.57
52 Week Low 0.00
ZLCS Important Levels
Resistance 2 1.34
Resistance 1 1.27
Pivot 1.20
Support 1 1.09
Support 2 1.02
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
QKLS 0.12 -36.84%
More..

Zalicus Inc. (NASDAQ: ZLCS)

ZLCS Technical Analysis 2
As on 15th Jul 2014 ZLCS Share Price closed @ 1.18 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.57 & Buy for SHORT-TERM with Stoploss of 1.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
ZLCS Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ZLCS Other Details
Segment EQ
Market Capital 70786440.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.zalicus.com
ZLCS Address
ZLCS
245 First Street
Third Floor
Cambridge, MA 02142
United States
Phone: 617-301-7000
Fax: 617-301-7010
Interactive Technical Analysis Chart Zalicus Inc. ( ZLCS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Zalicus Inc.
ZLCS Business Profile
Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. It focuses on the discovery and development of selective ion channel modulators and its combination high throughput screening technology (cHTSTM) to discover new product candidates for its portfolio or for its collaborators in the areas of pain, inflammation, oncology and infectious disease.